Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors - Takeaways - MDSpire

Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors

  • By

  • Amr Elgehiny

  • Aaron E. Fan

  • Maria Frost

  • Jiasen He

  • Sam E. Gary

  • Diana S. Osorio

  • Wafik Zaky

  • Li Zhou

  • Kyung-Don Kang

  • Zhuo Zhang

  • Juan Fueyo

  • Candelaria Gomez-Manzano

  • Eric M. Thompson

  • Joshua D. Bernstock

  • Gregory K. Friedman

  • February 25, 2026

  • 0 min

Share

  • 1

    Pediatric CNS tumors are the leading cause of cancer-related death in children, highlighting the need for more effective therapies.

  • 2

    Oncolytic virotherapy, particularly using oncolytic herpes simplex virus (oHSV), shows promise in treating pediatric CNS tumors.

  • 3

    The first completed clinical trial of oncolytic virotherapy in pediatric CNS tumors involved G207, demonstrating safety and preliminary efficacy.

  • 4

    G207 treatment resulted in a median overall survival of 12.2 months, significantly better than the historical median of 5.6 months for recurrent pediatric high-grade glioma.

  • 5

    Ongoing research indicates that pediatric high-grade brain tumor cells are more sensitive to oHSV than adult high-grade glioma cells.

Original Source(s)

Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors

  • by Amr Elgehiny, Aaron E. Fan, Maria Frost, Jiasen He, Sam E. Gary, Diana S. Osorio, Wafik Zaky, Li Zhou, Kyung-Don Kang, Zhuo Zhang, Juan Fueyo, Candelaria Gomez-Manzano, Eric M. Thompson, Joshua D. Bernstock, Gregory K. Friedman

  • February 25, 2026

Related Content

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study

Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases

Dana-Farber Research News 04.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 - 31.

  • by

  • April 15, 2026

  • 22 min